Physician profile
Jerri P Sethna
NPI 1649236415
$13,331.21
in general payments reported to CMS, 2019-2025
30 companies · $2,588 in 2025
The $2,588 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,090 · 2020: $1,240 · 2021: $621 · 2022: $1,976 · 2023: $2,627 · 2024: $3,189 · 2025: $2,588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,292 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,292.16 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $2,400.90 | 2019-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $1,483.31 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Teva Pharmaceuticals USA, INC. | $1,381.49 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Abbvie INC. | $1,176.06 | 2021-2025 | Vraylar |
| Alkermes, INC. | $785.69 | 2022-2025 | Lybalvi, Aristada |
| Vanda Pharmaceuticals INC. | $741.66 | 2019-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $695.81 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $653.94 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $649.60 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $514.84 | 2023-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $477.50 | 2024-2025 | Cobenfy |
| Allergan, INC. | $454.25 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $338.02 | 2019-2024 | Trintellix |
| Validus Pharmaceuticals LLC | $226.61 | 2023-2025 | Equetro, Equetro, Raldesy |
| Axsome Therapeutics, INC. | $211.63 | 2022-2025 | Auvelity |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $210.08 | 2019-2020 | |
| Eisai INC. | $148.40 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $93.52 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $90.61 | 2022-2025 | Qelbree, Qelbree |
| Avanir Pharmaceuticals, INC. | $87.24 | 2019-2022 | |
| Harmony Biosciences LLC | $81.26 | 2022-2024 | |
| Ironshore Pharmaceuticals INC. | $76.74 | 2019-2023 | Jornay Pm |
| Corium, LLC | $76.57 | 2022-2023 | Azstarys |
| Shire North American Group INC | $67.32 | 2019 | |
| Idorsia Pharmaceuticals US INC | $64.01 | 2023-2024 | Quviviq |
| Noven Therapeutics, LLC | $59.54 | 2020-2021 | |
| Janssen Biotech, INC. | $27.38 | 2023 | |
| Sun Pharmaceutical Industries INC. | $22.23 | 2021 | |
| Bausch Health US, LLC | $17.83 | 2022 | |
| Almatica Pharma LLC | $17.17 | 2025 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerri Sethna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.